Candidemia Pipeline Insight
DelveInsight’s, “Candidemia – Pipeline Insights, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Candidemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Candidemia is defined as the presence of Candida species in the blood. It is the most common fungal bloodstream infection in hospitalized patients.
Candida albicans is the most common cause of candidemia, representing 35% to 60% of isolates. Candida parapsilosis, Candida tropicalis, Candida glabrata and Candida krusei, are the most common nonalbicans Candida species identified in cultures. Most common risk factors include critical illness and prolonged intensive care unit stay. The presence of a central venous catheter, antibiotic exposure, abdominal surgery (especially if repeated laparotomies or anastomotic leakage is present), malignancy (solid organ and hematologic), acute necrotizing pancreatitis, organ transplant recipients, and total parenteral nutrition are other major risk factors.
The symptoms of Candidemia include:
- Fever, chills
- Skin rash
- Generalized weakness or fatigue
- Low blood pressure
- Muscle aches
- Vision changes or signs of an eye infection
- Headaches and neurological deficits
- Abdominal pain
Diagnosis of candidemia is based on direct fungal detection in blood cultures. The advantage of cultures is the ability to do susceptibility testing. Biopsy should be done in patients with localized findings and sent for culture and gram staining. The diagnosis can also be made by detecting antigens of Candida in the blood stream. New polymerase chain reaction tests are being developed and evaluated in clinical trials.
Early empiric antifungal therapy should be strongly considered in critically ill patients with risk factors for invasive candidiasis in whom the disease is suspected, as some studies have shown reduced mortality with this strategy. The decision to start therapy should be based on clinical suspicion, risk factors, and surrogate markers of candidemia (e.g., B-d-glucan). Empiric therapy should start with an echinocandin (caspofungin, micafungin, anidulafungin) as first choice therapy. Fluconazole may be considered in certain patients who are not critically ill and in whom susceptibility to fluconazole is likely. Amphotericin B can be given to patients with intolerance or contraindications to other treatments. Transition to fluconazole is recommended for stable patients in whom cultures have resulted in sensitive Candida species, such as C. albicans.
Candidemia Emerging Drugs Chapters
This segment of the Candidemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Candidemia Emerging Drugs
- Rezafungin acetate: Cidara Therapeutics
Rezafungin acetate is a drug that is a glucan synthase inhibitor. It works by blocking substance P, a small signaling molecule. Originally, this compound was owned by Seachaid Pharmaceuticals. Rezafungin acetate is now licensed by Mundipharma International and under the development of Cidara Therapeutics.
- Fosmanogepix: Amplyx Pharmaceuticals
Fosmanogepix has a novel mechanism of action that inhibits the highly conserved fungal enzyme Gwt1, which is essential for trafficking and anchoring mannoprotein to the outer cell wall in fungi. Fosmanogepix is currently in Phase 2 clinical trials evaluating the efficacy and safety of both intravenous (IV) and oral formulations for the treatment of patients with fungal infections caused by aspergillosis and candidemia, including candidemia caused by C. auris.
Further product details are provided in the report……..
Candidemia: Therapeutic Assessment
This segment of the report provides insights about the different Candidemia drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Candidemia
There are approx. 3+ key companies which are developing the therapies for Candidemia. The companies which have their Candidemia drug candidates in the most advanced stage, i.e. phase III include, Cidara Therapeutics.
DelveInsight’s report covers around 3+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Candidemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Candidemia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Candidemia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Candidemia drugs.
- The companies and academics are working to assess challenges and seek opportunities that could influence Candidemia R&D. The therapies under development are focused on novel approaches to treat/improve Candidemia.
Candidemia Report Insights
- Candidemia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Candidemia Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Candidemia drugs?
- How many Candidemia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Candidemia?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Candidemia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Candidemia and their status?
- What are the key designations that have been granted to the emerging drugs?
- Cidara Therapeutics
- Amplyx Pharmaceuticals
- Rezafungin acetate